Skip to Main Content

Author Details

Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
1998
233
56
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37822035MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.Eur J Haematol2024
36630200Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.Blood Cancer Discov2023
37735558Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.Leukemia2023
37024519What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?Leukemia2023
36951151Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.Haematologica2023
37085611UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.Leukemia2023
37245522CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Haematol2023
37407322[Treating high-risk myelodysplastic syndromes].Bull Cancer2023
37433887Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).Leukemia2023
36724453Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.Blood2023
36475522Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes.Haematologica2023
36779592Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.Haematologica2023
36773040Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.Ann Hematol2023
36737440Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.Nat Commun2023
36736290Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.Cell Stem Cell2023
36930857Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.J Clin Oncol2023
36455187Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.J Clin Oncol2023
34632574Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.Br J Dermatol2022
35443031Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.Blood2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35438802A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.Br J Haematol2022
35797337Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.PLoS One2022
35579092Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.Clin Exp Rheumatol2022
35728048Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.Blood Adv2022
35750691A multiparametric niche-like drug screening platform in acute myeloid leukemia.Blood Cancer J2022
35355897Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study.Open Forum Infect Dis2022
35654824Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation.Bone Marrow Transplant2022
36570694Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively.Hemasphere2022
36071100Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.Leukemia2022
36104395A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.Leukemia2022
36201165Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.Clin Cancer Res2022
36088307Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory.BMC Cancer2022
36151081Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML.Blood Cancer J2022
34985763The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients.Vox Sang2022
35072371The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs.Cancer J2022
34788403Clinical, pathological, and molecular features of myelodysplasia cutis.Blood2022
32581253Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.Leukemia2021
33881523Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.Blood2021
33626866Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.Haematologica2021
33600210Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).J Clin Oncol2021
33570629Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.Blood Adv2021
33623140Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.Leukemia2021
33483617Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.Leukemia2021
33564192Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.Nat Med2021
33564086Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.Leukemia2021
34410352Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.Blood2021
34789825Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.Leukemia2021
34671345Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.Front Immunol2021
34495287UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome.JAMA Dermatol2021
34638998BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.Int J Mol Sci2021
  • 1 - 50 of 233

Recommended Authors

Lohith Gowda
Yale Cancer Center and Yale School of Medicine
Career Start Year 2018
Number of shared co-authors 1
Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 5
Hein Than
Singapore General Hospital
Career Start Year 2012
Number of shared co-authors 2
Patricia Kropf
Novant Health Cancer Institute - Elizabeth
Career Start Year 2009
Number of shared co-authors 7
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 23
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 7
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 13
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 15
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 4
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 8
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 8
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 6
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 2
Gudrun G??hring
Hannover Medical School
Career Start Year 2002
Number of shared co-authors 10
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 14
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 12
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 16
Thoralf Lange
Hospital Weissenfels
Career Start Year 1994
Number of shared co-authors 4
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 1
Jorge Cortes
Georgia Cancer Center
Career Start Year 1991
Number of shared co-authors 23
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 26
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 19
Clayton A Smith
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 0
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 10
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 5
Dietger Niederwieser
University of Leipzig
Career Start Year 1982
Number of shared co-authors 11
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 4

Collaborators

Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 57
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 52
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 45
Thorsten Braun
Centre Hospitalier Universitaire Hopital Avicenne
Co-authored papers 35
Claude Gardin
Avicenne Hospital
Co-authored papers 35
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 26
Emmanuelle Clappier
Saint-Louis Hospital
Co-authored papers 24
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Co-authored papers 24
Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Co-authored papers 11
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Co-authored papers 11
Jean Soulier
University of Paris
Co-authored papers 11
Luca Malcovati
University of Pavia & S. Matteo Hospital
Co-authored papers 8
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 7
Hugues de Th??
Universite Paris Cite, Inserm, CNRS, Institut de Recherche Saint-Louis
Co-authored papers 7
Cl??mentine Chauvel
Universite Paris Cite, INSERM, CNRS
Co-authored papers 6
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 6
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Co-authored papers 5
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 4
Felicitas Thol
Hannover Medical School
Co-authored papers 4
Anna Raimbault
CHU La Miletrie University Hospital Poitiers France.
Co-authored papers 4
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 4
Elie Azoulay
Paris Cite University
Co-authored papers 4
Marie-H??l??ne Schlageter
Universite de Paris, U1 INSERM
Co-authored papers 4
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 3
Benjamin L Ebert
Co-authored papers 3
Michael Heuser
Hannover Medical School
Co-authored papers 3
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 3
Donna Neuberg
Co-authored papers 3
Jeannig Berrou
Universite Paris Cite, Institut de Recherche Saint-Louis
Co-authored papers 3
Justine Penneroux
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
Release 1.2